Recommended

Download this feature partnership: Continuous manufacturing: an evolving technology for drug substance manufacturing
New webinar: Defining the right digital strategy for oncology: What do you want to measure?
Join now: Pharmaceutical continuous manufacturing: what’s next for industry?
Register now for our upcoming webinar: Enhancing oral drug delivery: Exploring multiparticulate systems
Download our latest in-depth focus to read articles on single temperature incubation, endotoxin standards and aseptic connections in pharma manufacturing.
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps
Register now: Simplifying complex dosage forms with advanced encapsulation
Join our webinar: Unmasking the unknown: how mass spectrometry delivers accurate identifications
news

Pfizer receives EU haemophilia B gene therapy approval

The single-dose gene therapy was approved for certain patients with haemophilia B in the US and Canada earlier this year, marketed as BEQVEZ.

DURVEQTIX gene therapy haemophilia B

A conditional marketing authorisation in Europe has been grated for the gene therapy DURVEQTIX ® (fidanacogene elaparvovec), to treat severe and moderately severe haemophilia B (congenital factor IX deficiency) in adults.

This new regulatory approval by the European Commission is indicated for patients without a history of factor IX inhibitors and without detectable antibodies to variant AAV serotype Rh74.

More about the gene therapy

The one-time gene therapy contains a “bio-engineered adeno-associated virus (AAV) capsid and a high-activity variant of human coagulation FIX gene”, Pfizer shared. This enables individuals with the rare genetic bleeding disorder to produce factor IX (FIX) themselves, instead of regular intravenous FIX infusions, the company noted.

DURVEQTIX was approved by the US Food and Drug Administration (FDA) for haemophilia B as BEQVEZTM in April this year.

DURVEQTIX has shown the potential to offer long-term bleed protection in a one-time dose, reducing or eliminating bleeds for the appropriate patients with haemophilia B”

The current standard of care for treating patients with haemophilia B, requires “frequent infusions and many remaining at risk of breakthrough bleeds that can lead to pain and restricted mobility,” explained Alexandre de Germay, Chief International Commercial Officer and Executive Vice President, Pfizer.

“[However,] DURVEQTIX has shown the potential to offer long-term bleed protection in a one-time dose, reducing or eliminating bleeds for the appropriate patients with haemophilia B,” de Germay continued.

The European Commission’s decision for DURVEQTIX is valid in all 27 EU member states, in addition to Iceland, Liechtenstein, and Norway.

About the DURVEQTIX Phase III study

The conditional marketing authorisation is based on results from the pivotal Phase III BENEGENE-2 study, which showed DURVEQTIX enabled a “significantly” reduced frequency of bleeding episodes compared with usual care. The company highlighted that the median annualised bleed rate (ABR) of zero bleeds was observed in the haemophilia B patients after up to four years of follow-up, Pfizer shared.

The pharmaceutical company licensed the gene therapy DURVEQTIX from Spark® Therapeutics in December 2014.